Company
ElancoDetails
Based on serology and virus isolation of chicken flocks, Chicken Anemia Virus (CAV) is present worldwide. CAV was first isolated in 1979 in Japan. Since then, an increasing interest was paid to this virus, as it was found to have a great impact on poultry industry in all major chicken-producing countries of the world. CAV is an immunosuppressive agent causing economic losses by inducing poor general performance and interfering with the immune response to vaccines. Based on the clinical or subclinical CAV infection on immune response, the infection has been related to increased susceptibility to other agents such as infectious bursal disease virus (IBDV). In addition, presence of CAV antibodies at slaughter has a substantial and significant negative effect on the broiler performance and profitability. The most effective method to control the disease is to vaccinate breeder flocks before the onset of lay. In order to guarantee effective protection against CAV, parent flocks must have high and uniform antibody levels throughout the whole laying period. Currently there are several CAV live vaccines available with CAV vaccine strains of different attenuation levels which present different immunogenic properties. Combination of vaccination and monitoring of CAV antibody titers in breeders and their progeny ensure effective protection against CAV and decreases the economic losses. During this one-hour educational webinar learn about the effects of CAV infection on other pathogens, the best strategies to prevent CAV-induced immunosuppression and the new tools for monitoring the immunization programs.
This webinar is sponsored by Elanco and presented by WATT Global Media.